TICKERNOMICS Sign up
Last Update: 2024-03-28 02:18:09
Batm Advanced Communications Ltd ( BVC.LSE ) https://www.batm.com
0.24USD
Sector:
Healthcare
Industry:
Medical Instruments & Supplies
Country:
Israel
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-9.21%
BVC.LSE
SPY
32.74%
-81.28%
BVC.LSE
SPY
92.93%
-60.68%
BVC.LSE
SPY
224.41%
-12.91%
BVC.LSE
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
105.48
97.31
0.30
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
42.09
0.33
0.91
-1.14
0.00
0.00
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
8.0373
66.24
64.77
1.01
Other Earnings and Cash Flow Stats:
Batm Advanced Communications Ltd ( BVC.LSE ) Net Income TTM ($MM) is 0.00
Batm Advanced Communications Ltd ( BVC.LSE ) Operating Income TTM ($MM) is 0.00
Batm Advanced Communications Ltd ( BVC.LSE ) Owners' Earnings Annual ($MM) is 0.71
Batm Advanced Communications Ltd ( BVC.LSE ) Current Price to Owners' Earnings ratio is 150.12
Batm Advanced Communications Ltd ( BVC.LSE ) EBITDA TTM ($MM) is 0.00
Batm Advanced Communications Ltd ( BVC.LSE ) EBITDA Margin is 0.00%
Capital Allocation:
Batm Advanced Communications Ltd ( BVC.LSE ) has paid 0.00 dividends per share and bought back 6.317992 million shares in the past 12 months
Batm Advanced Communications Ltd ( BVC.LSE ) has reduced its debt by 14.196 million USD in the last 12 months
Capital Structure:
Batm Advanced Communications Ltd ( BVC.LSE ) Interest-bearing Debt ($MM) as of last quarter is 0
Batm Advanced Communications Ltd ( BVC.LSE ) Annual Working Capital Investments ($MM) are 2
Batm Advanced Communications Ltd ( BVC.LSE ) Book Value ($MM) as of last quarter is 116
Batm Advanced Communications Ltd ( BVC.LSE ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Batm Advanced Communications Ltd ( BVC.LSE ) has 33 million in cash on hand as of last quarter
Batm Advanced Communications Ltd ( BVC.LSE ) has 51 million of liabilities due within 12 months, and long term debt 5 as of last quarter
Batm Advanced Communications Ltd ( BVC.LSE ) has 436 common shares outstanding as of last quarter
Batm Advanced Communications Ltd ( BVC.LSE ) has 0 million USD of preferred stock value
Academic Scores:
Batm Advanced Communications Ltd ( BVC.LSE ) Altman Z-Score is -0.73 as of last quarter
Batm Advanced Communications Ltd ( BVC.LSE ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
Batm Advanced Communications Ltd ( BVC.LSE ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of Batm Advanced Communications Ltd ( BVC.LSE ) for the amount of $ on
26.21% of Batm Advanced Communications Ltd ( BVC.LSE ) is held by insiders, and 41.64% is held by institutions
Batm Advanced Communications Ltd ( BVC.LSE ) went public on 1970-01-01
Other Batm Advanced Communications Ltd ( BVC.LSE ) financial metrics:
FCF:-2.25
Unlevered Free Cash Flow:78.55
EPS:0.00
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:0.00
Beta:1.01
Buffet's Owners Earnings:0.71
Price to Owner's Earnings:150.12
About Batm Advanced Communications Ltd ( BVC.LSE ) :
BATM Advanced Communications Ltd., together with its subsidiaries, develops, produces, and markets real-time technologies in Israel, the United States, and Europe. It operates through two segments, Networking and Cyber, and Bio-Medical. The Networking and Cyber segment is involved in the research and development, production, and marketing of data communication products, including network function virtualization, edge computing, carrier ethernet and MPLS access solutions, cyber network monitoring, and network encryption. This segment also offers software services, such as training and technical support, laboratory service and maintenance; and construction contracts. The Bio-Medical segment offers molecular biology diagnostics; and solutions to treat pathogenic and medical waste in laboratories and hospitals, as well as for pharmaceutical manufacturing plants and agricultural applications. This segment also administers testing services; and distributes diagnostic equipment and medical supplies of various brands. The company was incorporated in 1992 and is headquartered in Hod Hasharon, Israel.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.